Highlights include continued progress with phase IIb psilocybin therapy clinical trial, launch of first Centre of Excellence, and expansion of Discovery Center Phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) on track to report data by end of 2021 First Centre of Excellence, a research facility and innovation lab, established at Sheppard Pratt…


Previous articleMindMed Announces C$19.5 Million Bought Deal Private Placement Offering
Next articleBetter Plant Appoints Branding Expert Perry Chua as Chief Creative Officer